Eli Lilly to invest $3bn in new Dutch manufacturing facility

Core Insights - Eli Lilly and Company plans to invest $3 billion in a new manufacturing facility in Katwijk, Netherlands, to enhance its global supply chain operations [1][6] - The facility will focus on increasing production capacity for oral medications, including orforglipron, a new treatment for obesity expected to receive regulatory filings by the end of 2025 [2][5] - The project is anticipated to create 500 permanent jobs and 1,500 temporary positions during the construction phase starting in 2026 [3] Manufacturing and Technology - The new facility will incorporate advanced technologies such as automated material handling, paperless systems, and spray-dried dispersion technology to improve the production of oral solid medicines [3] - Eli Lilly's existing European manufacturing footprint includes sites in Ireland, France, Spain, and Italy, with additional factories planned in Germany and the Netherlands to meet rising product demand [4] Strategic Expansion - The company is also expanding its manufacturing capabilities outside Europe, with developments planned in Puerto Rico, Virginia, and Texas [4] - Further announcements regarding two additional US manufacturing sites are expected in late 2025 or early 2026, reflecting the company's commitment to enhancing its global supply chain [5][6]